Furthermore, PBRM1, BAP1, and FOXC2 were shown to be significantly associated with aggressive early-stage ccRCC through target sequencing and immunohistochemistry in our previous study [11]. This evidence concerns the gene FOXC2 and nonpapillary renal cell carcinoma.